

NEW DIRECTIONS IN LEUKAEMIA RESEARCH

2 - 4 March, 2026

Adelaide Convention Centre

Adelaide, South Australia

PROGRAM

| Start Time | End Time | Paper # | Room |
|------------|----------|---------|------|
|------------|----------|---------|------|

SUNDAY 1 MARCH 2026

| | | | |
|-------|-------|---|---------|
| 08:00 | 18:00 | Exhibition booth build and exhibitor move-in. | HALL M |
| 15:00 | 18:00 | Speaker Support | Room L3 |

MONDAY 2 MARCH 2026

| | | | |
|-------|-------|-----------------------------------|-----------|
| 07:30 | 18:00 | Registration Opens | FOYER L&M |
| 07:30 | 18:00 | Exhibition & Poster Displays Open | HALL M |
| 08:00 | 17:00 | Speaker Support | ROOM L3 |

9:00 10:55 CONFERENCE OPENING & SESSION 1 - Myeloproliferative Neoplasms HALL L

| | | | |
|-------|-------|----|--|
| 9:00 | 9:05 | | Welcome and Conference Opening |
| 9:05 | 9:25 | | INVITED SPEAKER: Anna Steiner (MPN), Consumer Representative & Advocate in Blood Cancer Research |
| 9:25 | 9:55 | | INVITED SPEAKER: Professor John Crispino, St. Jude Children's Research Hospital |
| 9:55 | 10:25 | | INVITED SPEAKER: Dr Cavan Bennett, Walter and Eliza Hall Institute of Medical Research |
| 10:25 | 10:40 | 17 | From Mutation to Transformation: Acquired Mutations Transcriptionally Reprogram Haematopoietic Stem Cells to Drive MPN and Post-MPN AML, Dr Jasmin Straube, QIMR Berghofer |
| 10:40 | 10:55 | 89 | Targeting CALR myelofibrosis with antibody therapies, Chloe Thompson-Peach, The University of Adelaide |

| | | | | |
|-------|-------|--|-----------------------------|--------|
| 10:55 | 11:25 | | Morning Tea & Trade Display | HALL M |
|-------|-------|--|-----------------------------|--------|

11:25 12:40 SESSION 2 - Bone marrow microenvironment/Spatial Profiling HALL L

| | | | |
|-------|-------|----|--|
| 11:25 | 11:55 | | INVITED SPEAKER: Dr Raymond Yip, Walter and Eliza Hall Institute of Medical Research |
| 11:55 | 12:10 | 30 | The spatial organisation of the paediatric AML bone marrow, Prof. Dr. Olaf Heidenreich, Princess Maxima Center For Pediatric Oncology |
| 12:10 | 12:25 | 58 | Uncovering the in vivo dynamics of blood cancer cell death and clearance in the bone marrow microenvironment post-therapy, Dr Georgia Atkin-Smith, WEHI |
| 12:25 | 12:40 | 96 | Investigating ribosome-targeting therapies for the treatment of relapsed/ refractory multiple myeloma, A/Prof Elaine Sanij, St Vincent's Institute of Medical Research |

| | | | | |
|-------|-------|--|-----------------------|--------|
| 12:40 | 13:40 | | Lunch & Trade Display | HALL M |
|-------|-------|--|-----------------------|--------|

PROGRAM

| Start Time | End Time | Paper # | Room |
|---------------------------------|----------|---------|------|
| MONDAY 2 MARCH 2026 (CONTINUED) | | | |

| | | | | | |
|-------|-------|--|--|--|--------|
| 13:40 | 14:40 | SESSION 3 - Equity and Diversity in Sponsorship/Mentorship | | | HALL L |
| 13:40 | 14:10 | INVITED SPEAKER: | | | |
| 14:10 | 14:40 | INVITED SPEAKER: | | | |
| 14:40 | 15:00 | Rapid Fire Presentations 1 | | | |
| | | 11 | Therapy-induced mechanisms of adaptive resistance in T-cell Acute Lymphoblastic Leukaemia, Johnathon Lucas, University of Manitoba | | |
| | | 22 | Multi-Omic Profiling to Inform AML Treatment Strategies, Dr Heather Murray, The University of Newcastle | | |
| | | 28 | Defining the non-catalytic role of NSD2 in t(4;14) Multiple Myeloma, Mr Joshua King, Peter MacCallum Cancer Centre | | |
| | | 54 | Harnessing the gut-brain axis to reduce CNS toxicity in acute lymphoblastic leukaemia , Dr Elyse Page, SAHMRI | | |
| | | 70 | Distinct signalling networks and drug responses of JAK2 and NRAS mutant subclones in CRLF2-positive B-ALL, Ms Kaitlyn Kew, Olivia Newton John Cancer Research Institute | | |
| 15:00 | 15:30 | Afternoon Tea & Trade Display | | | HALL M |
| 15:30 | 17:05 | SESSION 4 - Myeloma | | | HALL L |
| 15:30 | 15:50 | INVITED SPEAKER: CAR-T therapy in myeloma - a new era, Professor Joy Ho (Clinical Spotlight), The University of Sydney | | | |
| 15:50 | 16:20 | INVITED SPEAKER: Preclinical optimization of T cell redirected therapy against multiple myeloma Associate Professor Marta Chesi, Mayo Clinic | | | |
| | | SPONSORED BY: THE BARRIE DALGLEISH CENTRE for Myeloma & Related Blood Cancers | | | |
| 16:20 | 16:50 | INVITED SPEAKER: Associate Professor Lev Kats, Peter MacCallum Cancer Centre | | | |
| 16:50 | 17:05 | 43 | CRISPR-Cas9-based functional genomic screening reveals the heme biosynthesis enzyme ALAD as a critical dependency for multiple myeloma tumour growth in vivo, Dr Emma Cheney, The University of Adelaide | | |
| 17:05 | 17:25 | Rapid Fire Presentations 2 | | | |
| | | 42 | Using Olink proteomics and single RNA sequencing to discover proteins that distinguish MGUS and multiple myeloma., Dr Melissa Cantley, The University of Adelaide | | |
| | | 52 | Inhibition of nicotinamide metabolism by the novel NAMPT inhibitor OT-82 potentiates venetoclax in paediatric and adult acute myeloid leukaemia models, Mawar Karsa, Children's Cancer Institute | | |
| | | 31 | Stag2 cohesin loss promotes myelodysplasia and leukaemia through chromatin regulation , Dr Jane Xu, Columbia University Irving Medical Center | | |
| | | 64 | Unravelling the epigenetic drivers of CHIP – MDS/CMML – AML progression through novel Methylation-Sensitive Regulatory Elements, Dr Mahmoud Bassal, Beth Israel Deaconess Medical Center | | |
| | | 87 | RAS pathway-mutant acute myeloid leukaemia is resistant to venetoclax but demonstrates sensitivity to anti-GM-CSF antibody therapy, Kelly Lim, The University of Adelaide | | |
| 17:30 | 19:30 | Welcome Reception & Poster Session | | | HALL M |

PROGRAM

| Start Time | End Time | Paper # | Room |
|----------------------|----------|---------|------|
| TUESDAY 3 MARCH 2026 | | | |

| | | | | |
|-------|-------|-----|---|---------------|
| 07:00 | 18:00 | | Registration Opens | |
| 08:00 | 18:00 | | Exhibition & Poster Displays Open | |
| 08:00 | 17:00 | | Speaker Support | |
| 07:30 | 08:45 | | Breakfast Session - Meet the Experts | GILBERT SUITE |
| 9:00 | 11:00 | | SESSION 5 - Acute Lymphoblastic Leukaemia | HALL L |
| 9:00 | 9:30 | | INVITED SPEAKER: Professor Jan Cools, HemaSphere | |
| 9:30 | 10:00 | | INVITED SPEAKER: Omics-enabled strategies for molecular and functional profiling in ALL, Associate Professor Jessica Nordlund, Uppsala University | |
| 10:00 | 10:30 | | INVITED SPEAKER: Dr Chelsea Mayoh, Children's Cancer Institute | |
| 10:30 | 10:45 | 62 | Decitabine-Based Therapy Reshapes Glucocorticoid Response in Pediatric ETP-ALL with Extent of Benefit Predicted by Epigenetic Features, Dr Yizhou Huang, Children's Cancer Institute | |
| 10:45 | 11:00 | 9 | Defining chemotherapy-induced stress response in T-cell Acute Lymphoblastic Leukemia, Ovini Amarasinghe, University of Manitoba | |
| 11:00 | 11:30 | | Morning Tea & Trade Display | HALL M |
| 11:30 | 12:50 | | SESSION 6 - Lymphoma | HALL L |
| 11:30 | 11:50 | | INVITED SPEAKER: Novel immunotherapies for B-cell lymphoma-do we know what we don't know?, Professor Eliza Hawkes (Clinical Spotlight), Olivia Newton John Cancer Research Institute at Austin Health | |
| 11:50 | 12:20 | | INVITED SPEAKER: Professor Ari Melnick, Weill Cornell Medicine College | |
| 12:20 | 12:35 | 51 | SOX11-induced reprogramming of B2 cells to a B1a-like phenotype promotes Mantle Cell Lymphoma in mice , Dr Tim Pieters, Ghent University | |
| 12:35 | 12:50 | 103 | Defining DDX3Y as a synthetic lethal target in DDX3X-mutated B-cell lymphomas, Dr Sam Greenall, Monash University | |

PROGRAM

| Start Time | End Time | Paper # | Room |
|------------|----------|---------|------|
|------------|----------|---------|------|



TUESDAY 3 MARCH 2026 (CONTINUED)

| | | | | |
|-------|-------|--|---|-------------|
| 12:50 | 13:50 | Lunch & Trade Display | | HALL M |
| 13:50 | 14:45 | SESSION 7 - Metcalf Oration | | HALL L |
| 13:50 | 14:00 | Metcalf Introduction - Associate Professor Charley de Bock | | |
| 14:00 | 14:45 | MetCalf Oration - Professor Richard Lock | | |
| 14:45 | 15:45 | SESSION 8 - New Investigator Event - Consumer Engagement and Involvement in Research | | HALL L |
| 14:45 | 15:00 | INVITED SPEAKER: | | |
| 15:00 | 15:15 | INVITED SPEAKER: | | |
| 15:15 | 15:45 | Q&A Panel discussion | | |
| 15:45 | 16:15 | Afternoon Tea & Trade Display | | HALL M |
| 16:15 | 18:00 | SESSION 9 - Myelodysplastic Syndrome and Acute Myeloid Leukaemia | | HALL L |
| 16:15 | 16:45 | INVITED SPEAKER: Professor Hamish Scott, SA Pathology | | |
| 16:45 | 17:15 | INVITED SPEAKER: Single cell multiomics reveal clonal and functional dynamics of MDS stem/progenitor cells during hypomethylating therapy, Dr Julie Thoms , University of New South Wales | | |
| 17:15 | 17:35 | 105 | USP48 Loss Increase Sensitivity to Hypomethylating Agents in Acute Myeloid Leukemia, Constanze Schneider, Dana Farber Institute | |
| 17:35 | 17:45 | 104 | Novel immunotherapy for TET2-mutated CMML, Professor Daniel Thomas, SAHMRI | |
| 17:45 | 18:00 | 63 | Mechanistic insights into how venetoclax-based therapy durably eradicates NPM1 mutated clones in acute myeloid leukaemia, Dr Fiona Brown, Walter and Eliza Hall Institute | |
| 18:00 | 19:00 | Break | | |
| 19:00 | Late | Conference Dinner | | WINE CENTRE |

PROGRAM

| Start Time | End Time | Paper # | Room |
|------------------------|----------|---------|------|
| WEDNESDAY 4 MARCH 2026 | | | |

| | | |
|-------|-------|-----------------------------------|
| 08:00 | 15:30 | Registration Opens |
| 08:00 | 15:30 | Exhibition & Poster Displays Open |
| 08:00 | 14:00 | Speaker Support |

| | | | | |
|-------|-------|---|---|--------|
| 08:00 | 08:45 | Meet-the-Editors Session Professor Andrew Roberts - Editor-in-Chief of Blood Professor Jan Cools - Editor-in-Chief of HemaSphere | SPONSORED BY:   | HALL L |
|-------|-------|---|---|--------|

| | | | | |
|-------|-------|--|--|--------|
| 9:00 | 11:00 | SESSION 10 - Acute Myeloid Leukaemia | | HALL L |
| 9:00 | 9:20 | INVITED SPEAKER: Dr Jad Othman (Clinical Spotlight), Royal North Shore Hospital | | |
| 9:20 | 9:50 | INVITED SPEAKER: Targeting epigenetic regulatory complexes in SETBP1-mutant myeloid malignancies, Associate Professor Julia Maxson , Knight Cancer Institute | | |
| 9:50 | 10:20 | INVITED SPEAKER: Professor Steven Lane, QIMR Berghofer | | |
| 10:20 | 10:35 | 57 | Targeting PAR1 in aggressive blood cancer: A novel strategy to eradicate leukemic stem cells, Dr Nunki Hassan, University of Sydney | |
| 10:35 | 10:50 | 82 | Cu-Later AML: Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia, Dr Alexander Lewis, Peter MacCallum Cancer Centre | |
| 10:50 | 11:00 | 97 | Real-World Outcomes of Older Adults with Acute Myeloid Leukaemia Before and During the Venetoclax Era: An Australasian Leukaemia and Lymphoma Group (ALLG) National Blood Cancer Registry (NBCR) Study, Dr Patrick Lawrence, Princess Alexandra Hospital | |

| | | | | |
|-------|-------|-----------------------------|--|--------|
| 11:00 | 11:30 | Morning Tea & Trade Display | | HALL M |
|-------|-------|-----------------------------|--|--------|

| | | | | |
|-------|-------|--|---|--------|
| 11:30 | 13:00 | SESSION 11 - Epigenetics/Gene Regulation in blood cancer | | HALL L |
| 11:30 | 12:00 | INVITED SPEAKER: Dr Lyndsey Montefiori, St. Jude Children's Research Hospital | | |
| 12:00 | 12:30 | INVITED SPEAKER: Coordinated targeting of epigenetic and transcriptional networks to exploit blood cancer dependency on dysregulated gene expression, Dr Jennifer Devlin , Peter MacCallum Cancer Centre | | |
| 12:30 | 12:45 | 21 | Drug-induced epigenetic memory enables rational and effective sequential therapy in Acute Myeloid Leukaemia, Dr Omer Gilan, Monash University | |
| 12:45 | 13:00 | 84 | Investigating RNA splicing alterations in leukaemia, Dr. Ashwin Unnikrishnan, University of New South Wales | |

| | | | | |
|-------|-------|-----------------------|--|--------|
| 13:00 | 14:00 | Lunch & Trade Display | | HALL M |
|-------|-------|-----------------------|--|--------|

| | | | | |
|-------|-------|---|--|--------|
| 14:00 | 15:50 | SESSION 12 - Targeting high-risk paediatric leukaemia | | HALL L |
| 14:00 | 14:20 | INVITED SPEAKER: Professor Rishi Kotecha (Clinical Spotlight), Perth Children's Hospital | | |
| 14:20 | 14:50 | INVITED SPEAKER: Dr Elliott Stieglitz, UCSF Benioff Children's Hospitals | | |
| 14:50 | 15:05 | 14 | Menin a therapeutic target in non-KMT2Ar T-ALL? , Dr. Steven Goossens, Ghent University | |
| 15:05 | 15:20 | 81 | Efficacy of novel targeted therapies in Down syndrome acute lymphoid leukaemia, Miss Kunjal Panchal, The Kids Research Institute Australia | |
| 15:20 | 15:50 | Conference Closing & Awards Presentation | | |
| 15:50 | | Close | | |

POSTER DISPLAYS

Posters will be displayed from Monday 2 March to Wednesday 4 March.

All poster presenters should be alongside their poster during the allocated poster session and during schedule breaktimes where possible.

| Paper # | Poster # | Theme | |
|---------|----------|-------------------------------|---|
| 11 | P1 | Acute Lymphoblastic Leukaemia | Therapy-induced mechanisms of adaptive resistance in T-cell Acute Lymphoblastic Leukaemia, Johnathon Lucas, University of Manitoba |
| 12 | P2 | Acute Lymphoblastic Leukaemia | Pharmacological inhibition of sclerostin protects bone from B-cell acute lymphoblastic leukaemia-mediated destruction, Dr Vincent Kuek, The Kids Research Institute Australia |
| 34 | P3 | Acute Lymphoblastic Leukaemia | Pre-clinical assessment of dinaciclib in treatment of high-risk infant B-cell acute lymphoblastic leukaemia, Dr Sung Chiu, The Kids Research Institute Of Australia |
| 46 | P4 | Acute Lymphoblastic Leukaemia | Co-targeting BCL-2 and MCL-1 (Via CDK9) in pre-clinical models of high-risk Acute Lymphoblastic Leukaemia (ALL), Dr Donia Moujalled, Walter And Eliza Hall Institute |
| 48 | P5 | Acute Lymphoblastic Leukaemia | SOX11 induces $\gamma\delta$ T-cell differentiation and synergizes with MYCN to drive LMO2 $\gamma\delta$ -like T-cell acute lymphoblastic leukemia, Dr Tim Pieters, Ghent University |
| 49 | P6 | Acute Lymphoblastic Leukaemia | Efficacy of NAMPT inhibition in Down Syndrome-associated Acute Lymphoblastic Leukaemia, Miss Amelia Dyton, The Kids Research Institute Australia |
| 83 | P7 | Acute Lymphoblastic Leukaemia | Comprehensive Clarity: How the ZERO Childhood Cancer sequencing program is driving deeper understanding of Acute Lymphoblastic Leukemia biology and prognosis., Miss Kimberly Dias, Children's Cancer Institute |
| 7 | P8 | Acute Lymphoblastic Leukaemia | Decoding the aberrant IL-7/STAT5 axis driving therapy resistance in T-ALL, Mr Johnathon Lucas, University of Manitoba |
| 18 | P9 | Acute Lymphoblastic Leukaemia | Extracellular vesicles induce leukaemogenesis in cytokine dependent parental Ba/F3 cells via horizontal transfer of CRLF2 p.F232C genomic material, Mr Maxim Buckley, University of Adelaide |
| 54 | P10 | Acute Lymphoblastic Leukaemia | Harnessing the gut-brain axis to reduce CNS toxicity in acute lymphoblastic leukaemia , Dr Elyse Page, SAHMRI |
| 56 | P11 | Acute Lymphoblastic Leukaemia | DUX4 Detective: Interrogating the DUX4 rearranged subtype of B-ALL for a molecular lead, Mr Thomas McGovern, SAHMRI |
| 80 | P12 | Acute Lymphoblastic Leukaemia | Modelling the CNS-niche in vitro to investigate therapeutic vulnerabilities in acute lymphoblastic leukaemia, Mr Luke Quinlan, South Australian Health And Medical Research Institute |
| 75 | P13 | Acute Lymphoblastic Leukaemia | Investigating TKI Resistance Using Novel CRISPR-generated NUP214::ABL1 and SFPQ::ABL1 Ph-like ALL Models, Mrs Shengjie Wang, Olivia Newton John Cancer Research Institute |
| 70 | P14 | Acute Lymphoblastic Leukaemia | Distinct signalling networks and drug responses of JAK2 and NRAS mutant subclones in CRLF2-positive B-ALL, Ms Kaitlyn Kew, Olivia Newton John Cancer Research Institute |
| 66 | P15 | Acute Lymphoblastic Leukaemia | New hope for the universally fatal TCF3::HLF-positive paediatric B-cell acute lymphoblastic leukaemia, Ms Zahra Sheybani, Children's Cancer Institute |
| 69 | P16 | Acute Lymphoblastic Leukaemia | New mouse model systems to study oncogenic fusions in high-risk childhood acute lymphoblastic leukaemia, Ms Kristy Yeats, Children's Cancer Institute |
| 71 | P17 | Acute Lymphoblastic Leukaemia | Investigating leukaemic intrinsic mechanisms of CD19+/- B-ALL relapse post-CAR T-cell therapy, Ms Evelyn Yang, Olivia Newton-John Cancer Research Institute |
| 15 | P18 | Acute Lymphoblastic Leukaemia | Improving Genomic Alignment Accuracy and Variant Detection for Acute Lymphoblastic Leukemia Patients: A Pan-Genome Graph Approach, Ashlee Thomson, Sahmri |
| 61 | P19 | Acute Lymphoblastic Leukaemia | The Short-Chain Fatty Acid Butyrate; a novel microbe-derived defence against Acute Lymphoblastic Leukaemia , Cate Cheney, SAHMRI |
| 72 | P20 | Acute Lymphoblastic Leukaemia | Mapping the AKR1C3 cis-regulome in acute lymphoblastic leukaemia to enhance targeted therapy with a new AKR1C3-activated prodrug, Hansen Kosasih, Children's Cancer Institute |
| 73 | P21 | Acute Lymphoblastic Leukaemia | Development of a novel microbiome screening method to predict late-effects risk in paediatric ALL survivors. , Joyce Mugabushaka, SAHMRI |

| Paper # | Poster # | Theme | |
|---------|----------|-------------------------------|---|
| 50 | P22 | Acute Myeloid Leukaemia | Targeting CD93 signalling to overcome venetoclax resistance in acute myeloid leukemia, A/Prof Jason Powell, Centre for Cancer Biology |
| 4 | P23 | Acute Myeloid Leukaemia | TP53-mutant acute myeloid leukemia is associated with a heightened inflammatory iScore signature in AML , Dr Rahul Bhargava, Fortis Memorial Research Institute |
| 19 | P24 | Acute Myeloid Leukaemia | DNMT3A mutation-driven chemoresistance arises from transcriptionally-primed quiescent leukemia stem cells in NPM1c-FLT3ITD AML, Dr Paniz Tavakoli Shirazi, Qimr Berghofer |
| 22 | P25 | Acute Myeloid Leukaemia | Multi-Omic Profiling to Inform AML Treatment Strategies, Dr Heather Murray, The University of Newcastle |
| 38 | P26 | Acute Myeloid Leukaemia | Destroying Leukaemia Stem Cells with inhibition of Aryl Hydrocarbon Receptor, Dr Alyona Oryshchuk, University of Auckland Waipapa Taumata Rau |
| 99 | P27 | Acute Myeloid Leukaemia | In vivo CRISPR activation screens identify novel tumour drivers of acute erythroid leukaemia, Dr Yexuan Deng, Walter And Eliza Hall Institute of Medical Research |
| 10 | P28 | Acute Myeloid Leukaemia | Investigating therapeutically targetable mechanisms of SNAI1-driven Acute Myeloid Leukaemia, Miss Lynda Truong, Hudson Institute of Medical Research |
| 13 | P29 | Acute Myeloid Leukaemia | Investigating the role of colony-stimulating factor 3 receptor (CSF3R) and runt-related transcription factor 1 (RUNX1) in the progression of acute myeloid leukemia (AML), Miss Tarindhi Ratnayake, Deakin University |
| 27 | P30 | Acute Myeloid Leukaemia | Restoring sensitivity to venetoclax in AML through inhibition of DNA-PK-mediated DNA repair , Miss Maddison Chambers, University of Newcastle |
| 47 | P31 | Acute Myeloid Leukaemia | Induction of interferon signalling dictates Menin inhibitor efficacy in NPM1 mutant AML, Mr Joseph Cefai, Peter MacCallum Cancer Centre |
| 26 | P32 | Acute Myeloid Leukaemia | Microenvironment-guided functional profiling of venetoclax–hypomethylating agent sensitivity and resistance in acute myeloid leukemia, Mr. Yohannes Kelifa Emiru, University of Newcastle |
| 41 | P33 | Acute Myeloid Leukaemia | Mutational analysis of DDX41 in myelodysplastic syndromes and acute myeloid leukaemia, Mr. Duy Nguyen, The University of Auckland |
| 87 | P34 | Acute Myeloid Leukaemia | RAS pathway-mutant acute myeloid leukaemia is resistant to venetoclax but demonstrates sensitivity to anti-GM-CSF antibody therapy, Kelly Lim, The University of Adelaide |
| 98 | P35 | Acute Myeloid Leukaemia | Engineered humanized stem cell model of clonal haematopoiesis with TP53 mutation, Mr. Hossein Anani, University of Adelaide |
| 106 | P36 | Acute Myeloid Leukaemia | Single-Cell MRD Assessment in AML Reveals Clonal Diversity and Genotype-Phenotype Discordance Missed by Bulk Methods, Mission Bio, |
| 55 | P37 | Chronic Lymphocytic Leukaemia | Dual mTORC1/2 inhibition by Torin 2 induces cytotoxic and cytostatic effects in in vitro models of chronic lymphocytic leukaemia (CLL), Dr Lauren Thurgood, Flinders University |
| 59 | P38 | Chronic Lymphocytic Leukaemia | Proteomic-led drug discovery reveals lipid and non-canonical PI3K pathways as therapeutic targets in chronic lymphocytic leukaemia, Dr Lauren Thurgood, Flinders University |
| 92 | P39 | Chronic Lymphocytic Leukaemia | Clinical significance of endogenous DNA modifications as biomarkers in chronic lymphocytic leukemia, Dr Daniel Gackowski, Nicolaus Copernicus University In Toruń |
| 5 | P40 | Chronic Lymphocytic Leukaemia | Developing a novel lipid-based imaging tool for the surveillance of chronic lymphocytic leukemia. , Miss Olivia Burling, Flinders University |
| 31 | P41 | Epigenetics | Stag2 cohesin loss promotes myelodysplasia and leukaemia through chromatin regulation , Dr Jane Xu, Columbia University Irving Medical Center |
| 64 | P42 | Epigenetics | Unravelling the epigenetic drivers of CHIP – MDS/CMML – AML progression through novel Methylation-Sensitive Regulatory Elements, Dr Mahmoud Bassal, Beth Israel Deaconess Medical Center |
| 74 | P43 | Epigenetics | Targeting Cohesin Mutations in Leukemia to identify druggable avenues., Dr Jisha Antony, University of Otago |
| 94 | P44 | Epigenetics | Profiling of RNA modifications in patients with chronic lymphocytic leukemia: Insights into potential biomarkers., Dr Marta Starczak, Nicolaus Copernicus University In Toruń |
| 95 | P45 | Epigenetics | Examining the efficacy of targeting mutant TET2 in AML, Ms Leeann Desouza, Centre For Cancer Biology, University of South Australia |

| Paper # | Poster # | Theme | |
|---------|----------|--|--|
| 91 | P46 | Genomics | Australian Familial Haematological Conditions Study – Exploring the utility of exome re-analysis and long-read genome sequencing in molecular diagnosis of inherited bone marrow failure and blood cancer predisposition syndromes. Dr Leanne de Kock, University of South Australia |
| 32 | P47 | Genomics | Addressing index hopping as a sensitivity-limiting factor in NGS-based MRD detection in AML, Miss Mariam Alhilali, The University of Auckland |
| 79 | P48 | Genomics | Hidden Drivers in Non-Coding Regions: UTR Alterations Promote Immune Checkpoint Dysregulation and Oncogenic Activity, Ms Fatimah Jalud, Olivia Newton John Cancer Research Institute |
| 86 | P49 | Genomics | Analysis of population and disease databases expands the genotypic and phenotypic landscape of ERG Deficiency Syndrome to include cardiovascular dysfunction, Ms Jiarna Zerella, Centre for Cancer Biology, CCB |
| 35 | P50 | Genomics | Exploiting the molecular crosstalk between RNA Polymerase II and epigenetic regulators - novel therapeutic opportunities in leukaemia/blood cancer, Ms. Shenali A. Ranasinghe, Peter MacCallum Cancer Centre |
| 24 | P51 | Genomics | Investigating the role of SAGA in Regulating RNA Polymerase-II-Dependent Transcription in Cancer, Yvonne Daniel, Peter MacCallum Cancer Centre, Parkville, VIC |
| 25 | P52 | Lymphoma | High Neoantigen Burden Predicts Improved Progression-Free Survival in Follicular Lymphoma Treated with Immune Checkpoint Inhibition, Dr Rakin Chowdhury, Pa Hospital |
| 90 | P53 | Myelodysplastic Syndrome | Ascorbate downregulates proinflammatory cytokines in a humanized model of TET2 clonal haematopoiesis and in patients with TET2 mutant chronic myelomonocytic leukaemia, Professor Daniel Thomas, SAHMRI, Adelaide University |
| 20 | P54 | Myeloma | Polyamine blocking therapy to limit multiple myeloma plasma cell growth, Dr Jacqueline Noll, University of Adelaide |
| 28 | P55 | Myeloma | Defining the non-catalytic role of NSD2 in t(4;14) Multiple Myeloma, Mr Joshua King, Peter MacCallum Cancer Centre |
| 40 | P56 | Myeloma | Elevated desmoglein-2 expression in multiple myeloma is a prognostic marker across genomic subtypes with impact on high-risk cytogenetics and a distinct gene expression profile, Dr Barbara McClure, Centre for Cancer Biology, University of South Australia and SA Pathology |
| 42 | P57 | Myeloma | Using Olink proteomics and single RNA sequencing to discover proteins that distinguish MGUS and multiple myeloma., Dr Melissa Cantley, The University of Adelaide |
| 44 | P58 | Myeloma | Overcoming Cereblon species specificity: development of an IMiD®-sensitive C57BL/KaLwRij murine model of multiple myeloma via Crbn1391V expression, Dr Emma Cheney, The University of Adelaide |
| 45 | P59 | Myeloma | The myeloma drug bortezomib induces gastrointestinal toxicity and peripheral neuropathy in mice that is influenced by the gut microbiota, Dr Krzysztof Mrozik, Adelaide University |
| 16 | P60 | Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia | Investigating the molecular basis of mRNA stability in leukaemia, Dr Mary-Jane Tsang, Peter MacCallum Cancer Centre |
| 77 | P61 | Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia | The role of Copy Number Aberrations in MPN leukaemic transformation driven by p53-loss, Dr Megan Bywater, QIMR Berghofer |
| 67 | P62 | Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia | RUNX1 and beyond: genetic mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukaemia, Miss Zuhail Naderi, South Australian Health And Medical Research Institute |
| 8 | P63 | Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia | Identification of common factors driving myelofibrosis, PhD Alban Johansson, QIMR Berghofer |
| 6 | P64 | Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia | JAK2V617F Directly Impairs NK and T Cell Maturation While the MPN Microenvironment Drives Immune Exhaustion, Mariana Medeiros, University of Sao Paulo/QIMR Berghofer |
| 33 | P65 | Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia | Genomic complexity and adaptive alterations underpin drug resistance in myeloid blast crisis chronic myeloid leukaemia cell lines , Adelina Fernandes, University of Adelaide |
| 23 | P66 | New Therapeutic Approaches | The molecular mechanisms of CDK10 and CDK20 in targeting transcription cycles dysregulated in leukaemia, Dr Salla Kyheröinen, Peter MacCallum Cancer Centre |
| 39 | P67 | New Therapeutic Approaches | Dysregulated transcription directs APOBEC mutagenesis through R-loop formation in multiple myeloma, Dr. Nenad Bartonicek, Peter MacCallum Cancer Centre |
| 36 | P68 | New Therapeutic Approaches | TR-107 has cytotoxic and anti-proliferative effects against Diffuse Large B-Cell Lymphoma through downregulation of key mitochondrial pathways., Mr Benjamin Davies, Flinders University |
| 52 | P69 | New Therapeutic Approaches | Inhibition of nicotinamide metabolism by the novel NAMPT inhibitor OT-82 potentiates venetoclax in paediatric and adult acute myeloid leukaemia models, Mawar Karsa, Children's Cancer Institute |
| 60 | P70 | New Therapeutic Approaches | Differential sensitivity of in vitro models of KMT2A-rearranged infant acute lymphoblastic leukaemia to menin inhibitors , Mr Stephen Dymock, The Kids Research Institute Australia |

| Paper # | Poster # | Theme | |
|---------|------------|---------------------------------|---|
| 65 | P71 | Paediatric Leukaemia | Venetoclax-based therapy as a bridge to haematopoietic stem cell transplantation in relapsed or refractory paediatric acute leukaemia, Dr Katherine Colman, Wehi |
| 101 | P72 | Paediatric Leukaemia | PICALM::MLLT10 in Childhood non-Down Syndrome Acute Megakaryoblastic Leukaemia, Sean Carter, The Royal Children's Hospital |
| 102 | P73 | Paediatric Leukaemia | Uncovering Germline Structural Variants in Paediatric Acute Myeloid Leukaemia, Luis Arriola-Martinez, University of South Australia |
| 68 | P74 | Stem Cells and Microenvironment | Bioengineered Adult Human Endothelial Cell Derived Haematopoietic Stem Cells Re-establish Haematopoiesis in Failed Bone Marrow., Dr Vashe Chandrakanthan, Adelaide University |
| 93 | P75 | Stem Cells and Microenvironment | Modelling Disease Manifestation in Hereditary Haematological Malignancies, Dr Parvathy Venugopal, Centre For Cancer Biology |
| 76 | P76 | Stem Cells and Microenvironment | Impact of Oxygen Levels on Haematopoietic Stem Cell Development – Refining Methods to Investigate Molecular Changes During Endothelial-to-Haematopoietic Transition, Mr Luke Bland, Adelaide University |